Presepsin Teardown - Pitfalls of Biomarkers in the Diagnosis and Prognosis of Bacterial Infection in Cirrhosis
Overview
Authors
Affiliations
Aim: To evaluate the diagnostic and prognostic value of presepsin in cirrhosis-associated bacterial infections.
Methods: Two hundred and sixteen patients with cirrhosis were enrolled. At admission, the presence of bacterial infections and level of plasma presepsin, serum C-reactive protein (CRP) and procalcitonin (PCT) were evaluated. Patients were followed for three months to assess the possible association between presepsin level and short-term mortality.
Results: Present 34.7 of patients had bacterial infection. Presepsin levels were significantly higher in patients with infection than without (median, 1002 pg/mL 477 pg/mL, < 0.001), increasing with the severity of infection [organ failure (OF): Yes No, 2358 pg/mL 710 pg/mL, < 0.001]. Diagnostic accuracy of presepsin for severe infections was similar to PCT and superior to CRP (AUC-ROC: 0.85, 0.85 and 0.66, respectively, = NS for presepsin PCT and < 0.01 for presepsin CRP). At the optimal cut-off value of presepsin > 1206 pg/mL sensitivity, specificity, positive predictive values and negative predictive values were as follows: 87.5%, 74.5%, 61.8% and 92.7%. The accuracy of presepsin, however, decreased in advanced stage of the disease or in the presence of renal failure, most probably because of the significantly elevated presepsin levels in non-infected patients. 28-d mortality rate was higher among patients with > 1277 pg/mL compared to those with ≤ 1277 pg/mL (46.9% 11.6%, < 0.001). In a binary logistic regression analysis, however, only PCT (OR = 1.81, 95%CI: 1.09-3.01, = 0.022) but neither presepsin nor CRP were independent risk factor for 28-d mortality after adjusting with MELD score and leukocyte count.
Conclusion: Presepsin is a valuable new biomarker for defining severe infections in cirrhosis, proving same efficacy as PCT. However, it is not a useful marker of short-term mortality.
Wejnaruemarn S, Susantitaphong P, Komolmit P, Treeprasertsuk S, Thanapirom K World J Gastroenterol. 2025; 31(6):99506.
PMID: 39958447 PMC: 11752710. DOI: 10.3748/wjg.v31.i6.99506.
Efremova I, Maslennikov R, Poluektova E, Medvedev O, Kudryavtseva A, Krasnov G World J Hepatol. 2024; 16(5):822-831.
PMID: 38818295 PMC: 11135270. DOI: 10.4254/wjh.v16.i5.822.
Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.
Efremova I, Maslennikov R, Poluektova E, Medvedev O, Kudryavtseva A, Krasnov G Int J Mol Sci. 2024; 25(4).
PMID: 38396668 PMC: 10888218. DOI: 10.3390/ijms25041988.
Zanetto A, Pelizzaro F, Mion M, Bucci M, Ferrarese A, Simioni P United European Gastroenterol J. 2023; 11(9):815-824.
PMID: 37792602 PMC: 10637119. DOI: 10.1002/ueg2.12472.
Igna R, Girleanu I, Cojocariu C, Huiban L, Muzica C, Singeap A J Clin Med. 2022; 11(18).
PMID: 36143057 PMC: 9501308. DOI: 10.3390/jcm11185410.